EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer - 102017

Spotlight
Video

EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer

VJOncology has 824 videos Subscribe Here

Loading........
Description: The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment of urothelial cancer patients with high PD-L1 expression. Here, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, London, UK, explains the reasoning behind this development, and shares his insights on why this is a positive movement towards more personalized treatment for patients. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Shared By : VJOncology
Posted on : 08/22/18
Added : 9 months ago
Category : Bladder Cancer